This agent targets the overexpression of histone deacetylase (HDAC) or the aberrant recruitment of HDACs to oncogenic transcription factors in cancer cells. Vorinostat was approved on October 6, 2006, for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent, or recurrent disease following 2 systemic therapies.
Zolinza
VorinostatMerckFirst-in-class histone deacetylase inhibitor approved for cutaneous T-cell lymphoma
This agent targets the overexpression of histone deacetylase (HDAC) or the aberrant recruitment of HDACs to oncogenic transcription factors in cancer cells. Vorinostat was approved on October 6, 2006, for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent, or recurrent disease following 2 systemic therapies.
Safety. Pulmonary embolism and deep vein thrombosis have been reported in association with vorinostat. Patients receiving vorinostat therapy should be monitored for the pertinent signs and symptoms of these conditions. Dose-related thrombocytopenia and anemia have occurred with vorinostat and may require dose modification or discontinuation of therapy. Vorinostat therapy has been associated with gastrointestinal disturbances (eg, nausea, vomiting, and diarrhea). As such, patients may require antiemetics, antidiarrheals, and/or fluid or electrolyte replacement when taking the drug. Hyperglycemia has been observed in association with vorinostat therapy, necessitating the potential adjustment of diet and/or dosing. Vorinostat has been associated with prolongation of the QTc interval. Taking this into consideration, patients' electrolytes and electrocardiograms (ECGs) should be monitored at baseline and periodically during treatment. The most common adverse events associated with vorinostat therapy include diarrhea, fatigue, nausea, thrombocytopenia, anorexia, and dysgeusia.
Dosing. The recommended dose of vorinostat is 400 mg orally once daily with food. If a patient is intolerant to therapy, the dose may be reduced to 300 mg once daily with food. If necessary, the dose may be further reduced to 300 mg once daily with food for 5 consecutive days each week.
Ruxolitinib Cream Proves Safe for Young Children with Atopic Dermatitis
July 22nd 2024These results were found in the TRuE-AD3 study that was presented at the Society for Pediatric Dermatology meeting earlier this month, revealing the latest round of data collected in the TRuE-AD1 and TRuE-AD2 series of studies.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Issues Complete Response for High-Dose Opioid Rescue Med
July 16th 2024OX124 is a nasal spray provides rapid absorption of naloxone for patients experiencing an opioid overdose. The FDA would like to see additional technical data, as well as data on whether patients can correctly use the device.
Read More
Study Reveals Severe Impact of Atopic Dermatitis on Women's Quality of Life and Reproductive Health
July 15th 2024Although AD is a common condition, it’s impact on sexual function and reproductive health is not well understood. In addition, many women with AD are undertreated during pregnancy due to concerns about medication side effects.
Read More